St.Olavs Hospital HF
Trondheim, Norway
NCT Number: NCT05454319
The purpose of this study is to investigate feasibility, usability, safety, efficacy, and tolerability of Cerebri biofeedback treatment for adults with episodic migraine.
In the study, the app-based biofeedback treatment Cerebri for migraines in adults will be tested. By using biofeedback, bodily signals that are thought to be associated with migraines, are measured. During the treatment, one sensor is attached on the shoulder to measure activity in the shoulder and neck muscles and one sensor is attached to the index finger to measure temperature and heart rate variability. By getting on-screen feedback on the phone, the user can learn techniques to reduce muscle tension, and increase finger temperature and heart rate variability. Reduced muscle tension, as well as increase in finger temperature and heart rate variability is a sign of relaxation and a deactivation of the nervous system, which can lead to fewer and less serious migraine attacks.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Trondheim, Norway
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Home-based biofeedback with medical device
Other names: CEREBRI
Time frame: 3 months
Extraction of data from headache diary and completed biofeedback sessions
Time frame: 3 months
Mean mHealth app usability questionnaire (MAUQ) score at treatment week 1 and 12
Time frame: 3 months
Modified System Usability Scale (SUS) questionnaire score at treatment weeks 1 and 12
Time frame: 3 months
Change in the mean number of 28-day period migraine days from before treatment, to treatment weeks 1-4, weeks 5-8 and weeks 9-12.
Time frame: 3 months
Change in self-reported treatment efficacy by the Patient Global Impression of Change Scale (PGIC) from before treatment to end-of-treatment
Time frame: 3 months
Change in subject-reported, headache-related disability measured using the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQv2.1), from before treatment to end-of-treatment
Time frame: 3 months
Semi-structured interviews to evaluate design and ease of use of intervention, at treatment week 6 and 12, in a subset of subjects.
Nordic Brain Tech AS
Other Gov
A Prospective Feasibility Study of Daily, Home-based Biofeedback Therapy Using Cerebri for Migraine Treatment.
Acronym: CER-MIG-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04686136
Chronic Migraine, Episodic Migraine
Phoenix, Arizona, United States
View Trial DetailsNCT05207865
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04437433
Chronic Migraine, Episodic Migraine
Matsuyama, Ehime, Japan
View Trial DetailsNCT05853900
Brain Diseases, Central Nervous System Diseases
New York, United States
View Trial Details